Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2026
Oncological Outcomes for Primary Head and Neck Squamous Cell Carcinoma in the United Kingdom: Results From a National Cross-Sectional Cohort Study.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Green Frederick R, Williamson Andrew, Lim Alison E, Lee Ying Ki, Li Lucy, Moen Christy, Vasanthan Rishi, Wharf Olivia, Wong Jeremy, Paleri Vinidh, INTEGRATE Collaborators
Аннотация
OBJECTIVES: To investigate overall survival outcomes from primary head and neck squamous cell carcinoma (HNSCC) in the UK.
DESIGN: A retrospective national observational cohort study with consecutive participants.
SETTING: UK-wide head and neck cancer centres.
PARTICIPANTS: All patients with HNSCC who received a definitive treatment decision between 01/09/2021 and 30/11/2021. Subgroup analysis of patients was stratified by head and neck subsites.
MAIN OUTCOME MEASURES: Two-year overall (OS), disease-free (DFS), disease-specific (DSS), and local-recurrence-free-survival (LRFS) from primary HNSCC.
RESULTS: Data from 1488 patients was submitted by 50 centres, of which 1286 were primary HNSCC. Median age was 65.5 years (IQR 57-74), and 911 (71.0%) were male. The most common subsites were oropharynx (37.6%), oral cavity (28.3%), larynx (22.0%), and hypopharynx (6.8%). Treatment intent was curative in 79.9% of cases. Of treatment modalities, 529 (41.3%) underwent surgery, 874 (68.4%) underwent radiotherapy, and 391 (30.7%) underwent chemotherapy. Two-year OS, DFS, DSS and LRFS were 79.7%, 72.2%, 84.8%, and 75.1%, respectively. Two-year OS was 83.5%, 55.4%, 73.9% and 84.6% for laryngeal, hypopharyngeal, oral cavity and oropharyngeal subsites, respectively. On multivariate analysis, clinical T staging, age, ECOG performance status, and p16 status were independent prognostic factors for survival.
CONCLUSION: UK survival variations according to disease subsite reflect larger studies. Broader data over larger periods will reveal whether long-term improvements in the diagnosis, biological understanding, and treatments of HNSCC have translated into improvements in UK survival outcomes.
DESIGN: A retrospective national observational cohort study with consecutive participants.
SETTING: UK-wide head and neck cancer centres.
PARTICIPANTS: All patients with HNSCC who received a definitive treatment decision between 01/09/2021 and 30/11/2021. Subgroup analysis of patients was stratified by head and neck subsites.
MAIN OUTCOME MEASURES: Two-year overall (OS), disease-free (DFS), disease-specific (DSS), and local-recurrence-free-survival (LRFS) from primary HNSCC.
RESULTS: Data from 1488 patients was submitted by 50 centres, of which 1286 were primary HNSCC. Median age was 65.5 years (IQR 57-74), and 911 (71.0%) were male. The most common subsites were oropharynx (37.6%), oral cavity (28.3%), larynx (22.0%), and hypopharynx (6.8%). Treatment intent was curative in 79.9% of cases. Of treatment modalities, 529 (41.3%) underwent surgery, 874 (68.4%) underwent radiotherapy, and 391 (30.7%) underwent chemotherapy. Two-year OS, DFS, DSS and LRFS were 79.7%, 72.2%, 84.8%, and 75.1%, respectively. Two-year OS was 83.5%, 55.4%, 73.9% and 84.6% for laryngeal, hypopharyngeal, oral cavity and oropharyngeal subsites, respectively. On multivariate analysis, clinical T staging, age, ECOG performance status, and p16 status were independent prognostic factors for survival.
CONCLUSION: UK survival variations according to disease subsite reflect larger studies. Broader data over larger periods will reveal whether long-term improvements in the diagnosis, biological understanding, and treatments of HNSCC have translated into improvements in UK survival outcomes.